Answers are grounded in this paper and cite their sources.
Key Points Teriflunomide, the active metabolite of leflunomide, downregulates c-Myc expression through inhibition of PIM kinases. Leflunomide together with lenalidomide significantly extended survival in an in vivo MM model.
No takes yet. Share an insight, caveat, or question.
Buettner et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: